WASHINGTON UNIVERSITY, THE

• ST JUDE CHILDREN'S RESEARCH HOSPITAL INC

  UEI JL4JHE9SDRR3

  $1.6M

  Subcontractor to this prime · 3 sub-awards · latest Dec 17, 2024

  • National Institutes of Health
  • “OPTION 14B: ANTIGENIC CHARACTERIZATION & VACCINE ASSAY DEVELOPMENT (BOON) (MOD 21)”
  • “OPTION 14C: COVID-19 TRANSMISSION-II (BOON) (MOD 21)”
  • “OPTION 22B: REAGENT GENERATION- ANIMAL SERUM (BOON/DIAMOND) (MOD 16)”
• UNIVERSITY OF MARYLAND, BALTIMORE

  UEI Z9CRZKD42ZT1 · not in the directory yet

  $644.5K

  Subcontractor to this prime · 2 sub-awards · latest Nov 24, 2025

  • National Institutes of Health
  • “ADJUVANT DEVELOPMENT OF THE TLR4 LIGAND - BECC470S.”
  • “ADJUVANT DEVELOPMENT OF THE TLR4 LIGAND - BECC470S”
• VANDERBILT UNIVERSITY MEDICAL CENTER

  UEI GYLUH9UXHDX5

  $535K

  Subcontractor to this prime · 1 sub-award · latest Jul 2, 2024

  • Centers for Disease Control and Prevention
  • “IVY 5 - SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2”
• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  UEI C8H9CNG1VBD9

  $492.1K

  Subcontractor to this prime · 1 sub-award · latest May 22, 2024

  • National Institutes of Health
  • “OPTION 23B: 0258-A464-4609 WE FIRST OPTIMIZE THE MINIHA OVERALL CONSTRUCT AND IN PARALLEL DEVELOP CONSENSUS VARIANTS. IF BOTH SUCCESSFUL, IN A SECOND STEP, KNOWLEDGE FROM AIM 1 AND 2 WILL BE COMBINED TO DEVELOP A FOLDON INDEPENDENT CONSENSUS MINIHA FOR EACH GROUP 1, 2 AND IVB. AIM 1: DEVELOP HEADLESS MINI HA MOLECULES FOR H1 AND H3 HA WE WILL GENERATE TRIMERIC MINIHA. WE WILL FOCUS ON COMMONLY USED STRAINS (A/CA/04/09 PDMH1N1 (CAL/09) FOR GROUP 1, A/VICTORIA/361/11 H3N2 (VIC/11) FOR GROUP 2. WE ALSO INCLUDED H7. ONCE THESE VARIATIONS ARE ESTABLISHED AS STABLE, TRIMERIC PROTEINS, WE WILL APPROACH IVB STARTING WITH B/WA/02/19 B/VIC (B/WA/19). 1. OPTIMIZATION CUT SITE RECONNECTIONS. 2. OPTIMIZATION OF HELICAL INTERFACE CONTACTS. AIM 2: DEVELOP CONSENSUS HEADLESS MINI-HA TO TARGET INFLUENZA A AND B USING SEVERAL STRATEGIES TO CLUSTER INFLUENZA SEQUENCE ALIGNMENTS WE WILL GENERATE AS POSITION-SPECIFIC SCORING MATRIX (PSSM) TO GENERATE A CONSENSUS-BASED REDESIGN OF THE TEMPLATE STRUCTURE WHICH WILL BE TAKEN FROM VARIANTS OF AIM 1. TO AVOID BIAS CAUSED BY THE STARTING CRYSTAL STRUCTURE, WE WILL UTILIZE MULTIPLE TEMPLATES. CONSTRUCTS WILL BE EXPRESSED AND BIOCHEMICALLY EVALUATED. OPTION 12C: 0258-A483-4609 WE WILL ESTABLISH A METHOD FOR THE DETAILED EVALUATION OF NEUTRALIZATION POTENTIAL OR SERUM BINDING PROFILES. AIM 1: ASSAY OPTIMIZATION AND PROOF-OF-PRINCIPLE. WE WILL OPTIMIZE PSEUDOVIRUS TITERS AND IDENTIFY IDEAL EXPERIMENTAL CONDITIONS USING TWO HEMAGGLUTININ OF DIFFERENT INFLUENZA STRAINS AS PROTOTYPES. AIM 2: EVALUATION OF SENSITIVITY AND EVALUATION OF PREDEFINED ANTIBODY COMBINATIONS. WE WILL EXAMINE (1.) SURFACE DISPLAY OF HA AFTER PV INFECTION AND GENOME INTEGRATION TO STANDARDIZE THE BINDING ASSAY, (2) NEUTRALIZATION POTENTIAL AND SENSITIVITY USING 4 PREVIOUSLY CHARACTERIZED ANTIBODIES TO STEM, ANCHOR EPITOPE, RECEPTOR BINDING SITE AND LATERAL PATCH. AIM 3: LIBRARY GENERATION AND ESTABLISH POOL-BASED ANALYSIS. WE WILL GENERATE”
• UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  UEI MKAGLD59JRL1

  $482K

  Subcontractor to this prime · 1 sub-award · latest Feb 13, 2024

  • Defense Health Agency
  • “THE PAIN TRIAL IS A 4 YEAR (3-YEAR ENROLLMENT) MULTICENTER, PREHOSPITAL, RANDOMIZED, DOUBLE-BLIND, CLINICAL TRIAL COMPARING FENTANYL VERSUS SUB-DISSOCIATIVE KETAMINE FOR MORTALITY OUTCOME DIFFERENCES, SAFETY, AND ANALGESIA IN TRAUMA PATIENTS WITH COMPENSATED SHOCK.”
• NORTHWESTERN UNIVERSITY

  UEI KG76WYENL5K1

  $466.5K

  Subcontractor to this prime · 1 sub-award · latest May 26, 2026

  • National Institutes of Health
  • “CENTERS FOR RESEARCH ON STRUCTURAL BIOLOGY OF INFECTIOUS DISEASES”
• SEATTLE CHILDREN'S HOSPITAL

  UEI SZ32VTCXM799

  $36.3K

  Subcontractor to this prime · 1 sub-award · latest Sep 18, 2026

  • National Institutes of Health
  • “THE WASHINGTON UNIVERSITY IN ST. LOUIS, UNDER THE DIRECTION OF CRAIG SMITH, PH.D., WILL PERFORM THE FOLLOWING WORK TO SUPPORT THE BASIC PROJECT REQUIREMENT (9/1/2026-8/31/2027). A. STRUCTURAL BIOLOGY TRAINING: WUSTL WILL TRAIN UNDERGRADUATE STUDENTS HOW TO ANALYZE PROTEIN STRUCTURES. THE STUDENTS WILL WRITE MANUSCRIPTS DESCRIBING THE STRUCTURE AND (PREDICTED) FUNCTION OF SELECTED PROTEINS. IF POSSIBLE, ONE OR TWO STUDENTS WILL PARTICIPATE IN A SUMMER RESEARCH PROJECT FOCUSED ON CHARACTERIZING THE FUNCTION OF TARGET(S) USING A VARIETY OF LABORATORY METHODS. WUSTL WILL SUPPORT HIGH VALUE TARGETS (HVTS), COMMUNITY REQUEST PROJECTS (CRP), HIGHEST IMPACT PROJECTS (HIP) AND OTHER SPECIAL STUDIES WITHIN THE SSGCID PIPELINE, AS DECIDED BY THE SSGCID SCIENTIFIC LEADERSHIP TEAM (SLT). B. QUALITY CONTROL, DATA COLLECTION AND REPORTING: WUSTL WILL ESTABLISH AND CONDUCT QUALITY CONTROL PROCEDURES AS NECESSARY TO ENSURE THE PRODUCTION OF HIGH-QUALITY DATA. WUSTL WILL ENSURE THAT THE STATUS OF ALL WORK PERFORMED FOR SSGCID IS UPDATED IN A TIMELY FASHION, THROUGH THE CENTRAL TARGET TRACKING DATABASE (CTTDB), TRACKING SPREADSHEETS AND/OR ANY OTHER TRACKING SYSTEM REQUIRED BY THE PROJECT. KEY STAFF MEMBERS FROM WUSTL WILL PARTICIPATE IN SSGCID PROJECT MEETINGS AND NIAID-REQUIRED MEETINGS TO ENSURE THE SUCCESS OF THE PROJECT. WUSTL STAFF WILL CONTRIBUTE TO QUARTERLY AND SEMI-ANNUAL PROGRESS REPORTS AND ANY OTHER NIAID REQUIRED REPORTS AS NEEDED AND IN A TIMELY FASHION AND WILL CONDUCT THE PROJECT WORK WITH THE AIM OF PRODUCING IMPACTFUL PUBLICATIONS.”

• VANDERBILT UNIVERSITY MEDICAL CENTER

  UEI GYLUH9UXHDX5

  $5.9M

  Subcontracted by this company · 3 sub-awards · latest Oct 31, 2024

  • Centers for Disease Control and Prevention
  • “SCOPE OF WORK - VUMC THE OVERALL PURPOSE OF THE PROJECT INCLUDES THE FOLLOWING 4 TASKS: DESIGN A MULTI-SITE STUDY OF INFLUENZA TRANSMISSION WITHIN HOUSEHOLDS, ENROLL ELIGIBLE HOUSEHOLDS AND CONDUCT PROSPECTIVE STUDY ACTIVITIES, CONDUCT LABORATORY STUDIES TO CHARACTERIZE SUSCEPTIBILITY AND INFECTION, AND, PROVIDE DATA MANAGEMENT FOR SITUATIONAL AWARENESS AND ANALYSES. TO ACCOMPLISH THE PROJECT€„¢S OBJECTIVES, OUR VUMC SITE WILL ENROLL AND FOLLOW APPROXIMATELY 150 HOUSEHOLDS. VUMC WILL SERVE AS A SUBCONTRACTOR TO WASHINGTON UNIVERSITY AND WILL SERVE AS THE DATA COORDINATING CENTER (DCC) AND CENTRAL VIRAL LABORATORY FOR THE NETWORK. TO ENSURE EFFECTIVE AND EFFICIENT IDENTIFICATION OF INDEX CASES, REGARDLESS OF PRESENCE OF SYMPTOMS AND RAPID ENROLMENT AND COMPLETE FOLLOW-UP OF INDEX CASES AND HOUSEHOLD CONTACTS, WE WILL IMPLEMENT A MODIFIED CASE-ASCERTAINED STUDY DESIGN. WE WILL USE ESTABLISHED HIGH-THROUGHPUT STATE-OF-THE-ART TESTING PLATFORMS TO ACCURATELY IDENTIFY INFLUENZA INFECTIONS AND APPLY A DETAILED ALGORITHM TO DETERMINE AND VERIFY VACCINATION HISTORY. IN ADDITION, WE WILL IMPLEMENT AN INTEGRATED DATA SYSTEM FOR COLLECTION AND MANAGEMENT OF ALL STUDY ELEMENTS, THAT ENSURES REAL-TIME DATA SHARING.”
  • “SCOPE OF WORK C.1 BACKGROUND AND NEED THE SUBCONTRACTOR WILL BE VANDERBILT UNIVERSITY MEDICAL CENTER (VUMC) (NASHVILLE, TENNESSEE, USA). VUMC IS A NON-PROFIT 501(C) (3) HOSPITAL INCORPORATED IN THE STATE OF TENNESSEE. THE US ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) RECOMMENDS ANNUAL INFLUENZA VACCINATION FOR THOSE 6 MONTHS OLD OR OLDER. WHILE PRIOR INFLUENZA VACCINE EFFECTIVENESS (VE) STUDIES HAVE EVALUATED PREVENTION OF DISEASE IN DIFFERENT HEALTHCARE SETTINGS, THE IMPACT OF THESE VACCINES IN PREVENTING TRANSMISSION OF INFECTION REMAINS UNDERSTUDIED. MOREOVER, THE ONGOING STUDIES CONDUCTED DURING THE SARS-COV-2 PANDEMIC HAVE DOCUMENTED THAT THE RISK OF SECONDARY INFECTIONS IN HOUSEHOLDS HAVE BEEN CONSISTENTLY HIGHER THAN THOSE MEASURED WITH SIMILAR METHODOLOGIES PRIOR TO THE START OF THE PANDEMIC. THE IMPACT OF THOSE CHANGES IN TRANSMISSION RISK ON THE EFFECTIVENESS OF INFLUENZA VACCINES FOR PREVENTING TRANSMISSION REMAINS UNCLEAR. THE GOAL OF THIS STUDY IS TO ASCERTAIN SECONDARY INFECTION RISKS AND CONDUCT A ROBUST MULTI-CENTER EVALUATION OF INFLUENZA VE IN PREVENTING LABORATORY-CONFIRMED INFECTION TRANSMISSION IN HOUSEHOLDS. WE WILL PARTICIPATE IN COMPLETING ALL AIMS OUTLINED FOR THIS APPLICATION. WE WILL PARTICIPATE IN THE DESIGN AND ASSEMBLY OF A NETWORK OF 3 US RESEARCH SITES AND SERVE AS AN ENROLLING SITE AND AS THE DATA AND LABORATORY COORDINATING CENTER FOR THE NETWORK. WE WILL PARTICIPATE IN THE DESIGN AND EXECUTION OF A CASE-ASCERTAINED STUDY WITH DAILY COLLECTION OF DATA AND SPECIMENS TO ASSESS THE TRANSMISSION OF INFLUENZA INFECTIONS AND THE EFFECTIVENESS OF VACCINATION IN PREVENTING SUSCEPTIBILITY AND INFECTIVITY. WE WILL ALSO PARTICIPATE IN EXAMINING THE ROLE OF THERAPEUTICS, ISOLATION AND QUARANTINE ON THE FREQUENCY OF SECONDARY INFECTIONS IN HOUSEHOLDS. WE WILL HELP CHARACTERIZE IN DETAIL THE CLINICAL AND VIROLOGICAL COURSE OF SYMPTOMATIC, ASYMPTOMATIC AND PAUCI-SYMPTOMATIC INFECTIONS. OUR STUDY WILL BE LED BY INVESTI”
  • “1 SCOPE OF WORK C.1 BACKGROUND AND NEED THE SUBCONTRACTOR WILL BE VANDERBILT UNIVERSITY MEDICAL CENTER (VUMC) (NASHVILLE, TENNESSEE, USA). VUMC IS A NON-PROFIT 501(C) (3) HOSPITAL INCORPORATED IN THE STATE OF TENNESSEE. THE US ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) RECOMMENDS ANNUAL INFLUENZA VACCINATION FOR THOSE 6 MONTHS OLD OR OLDER. WHILE PRIOR INFLUENZA VACCINE EFFECTIVENESS (VE) STUDIES HAVE EVALUATED PREVENTION OF DISEASE IN DIFFERENT HEALTHCARE SETTINGS, THE IMPACT OF THESE VACCINES IN PREVENTING TRANSMISSION OF INFECTION REMAINS UNDERSTUDIED. MOREOVER, THE ONGOING STUDIES CONDUCTED DURING THE SARS-COV-2 PANDEMIC HAVE DOCUMENTED THAT THE RISK OF SECONDARY INFECTIONS IN HOUSEHOLDS HAVE BEEN CONSISTENTLY HIGHER THAN THOSE MEASURED WITH SIMILAR METHODOLOGIES PRIOR TO THE START OF THE PANDEMIC. THE IMPACT OF THOSE CHANGES IN TRANSMISSION RISK ON THE EFFECTIVENESS OF INFLUENZA VACCINES FOR PREVENTING TRANSMISSION REMAINS UNCLEAR. THE GOAL OF THIS STUDY IS TO ASCERTAIN SECONDARY INFECTION RISKS AND CONDUCT A ROBUST MULTI-CENTER EVALUATION OF INFLUENZA VE IN PREVENTING LABORATORY-CONFIRMED INFECTION TRANSMISSION IN HOUSEHOLDS. WE WILL PARTICIPATE IN COMPLETING ALL AIMS OUTLINED FOR THIS APPLICATION. WE WILL PARTICIPATE IN THE DESIGN AND ASSEMBLY OF A NETWORK OF 3 US RESEARCH SITES AND SERVE AS AN ENROLLING SITE AND AS THE DATA AND LABORATORY COORDINATING CENTER FOR THE NETWORK. WE WILL PARTICIPATE IN THE DESIGN AND EXECUTION OF A CASE-ASCERTAINED STUDY WITH DAILY COLLECTION OF DATA AND SPECIMENS TO ASSESS THE TRANSMISSION OF INFLUENZA INFECTIONS AND THE EFFECTIVENESS OF VACCINATION IN PREVENTING SUSCEPTIBILITY AND INFECTIVITY. WE WILL ALSO PARTICIPATE IN EXAMINING THE ROLE OF THERAPEUTICS, ISOLATION AND QUARANTINE ON THE FREQUENCY OF SECONDARY INFECTIONS IN HOUSEHOLDS. WE WILL HELP CHARACTERIZE IN DETAIL THE CLINICAL AND VIROLOGICAL COURSE OF SYMPTOMATIC, ASYMPTOMATIC AND PAUCI-SYMPTOMATIC INFECTIONS. OUR STUDY WILL BE LED BY INVE”
• THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  UEI QHF5ZZ114M72

  $1.9M

  Subcontracted by this company · 3 sub-awards · latest Oct 24, 2024

  • Centers for Disease Control and Prevention
  • “COLUMBIA UNIVERSITY IRVING MEDICAL CENTER SUBCONTRACT SCOPE OF WORK COLUMBIA UNIVERSITY IRVING MEDICAL CENTER WILL SERVE AS A SITE FOR THE RESPIRATORY VIRUS TRANSMISSION NETWORK (RVTN) TO STUDY HOUSEHOLD TRANSMISSION OF INFLUENZA. COLUMBIA UNIVERSITY IRVING MEDICAL CENTER WILL RECRUIT APPROXIMATELY 150 PARTICIPANTS WITH ACUTE INFLUENZA INFECTION AND THEIR HOUSEHOLD MEMBERS TO THE STUDY. USING STUDY MATERIALS PROVIDED BY WASHINGTON UNIVERSITY, COLUMBIA UNIVERSITY IRVING MEDICAL CENTER INVESTIGATORS WILL PROVIDE PARTICIPANTS WITH SELF-COLLECTION MATERIALS, COLLECT QUESTIONNAIRE DATA, MONITOR PARTICIPANT ACTIVITES, AND RECEIVE COMPLETED SAMPLES. COLUMBIA UNIVERSITY IRVING MEDICAL CENTER WILL STORE SAMPLES IN THE COLUMBIA UNIVERSITY IRVING MEDICAL CENTER LABORATORY AS DIRECTED BY THE PROTOCOL AND SHIP SAMPLES TO WASHINGTON UNIVERSITY OR OTHER DESIGNATED LABORATORY. THE SITE WILL ENTER DATA IN A TIMELY FASHION INTO THE REDCAP DATABASE. DR. MELISSA STOCKWELL, PROFESSOR OF PEDIATRICS AND POPULATION AND FAMILY HEALTH, WILL BE THE SITE PI ON THE SUBAWARD. SHE WILL BE RESPONSIBLE FOR ASSURING THAT ALL STUDY ACTIVITIES ARE CARRIED OUT AS OUTLINED IN THE PROTOCOL. SHE WILL OBTAIN AN IRB RELIANCE AGREEMENT WITH WASHINGTON UNIVERSITY AND MAINTAIN APPROVAL. SHE WILL HIRE AND OVERSEE STUDY STAFF TO CARRY OUT THE STUDY ACTIVITIES DESCRIBED ABOVE. SHE WILL ALSO SERVE ON THE STEERING COMMITTEE AS COLUMBIA UNIVERSITY IRVING MEDICAL CENTER€„¢S REPRESENTATIVE AND MAINTAIN FREQUENT CONTACT WITH THE STUDY PI DR. KWON.”
  • “COLUMBIA UNIVERSITY IRVING MEDICAL CENTER SUBCONTRACT SCOPE OF WORK THE OVERALL PURPOSE OF THE PROJECT INCLUDES THE FOLLOWING 4 TASKS: DESIGN A MULTI-SITE STUDY OF INFLUENZA TRANSMISSION WITHIN HOUSEHOLDS, ENROLL ELIGIBLE HOUSEHOLDS AND CONDUCT PROSPECTIVE STUDY ACTIVITIES, CONDUCT LABORATORY STUDIES TO CHARACTERIZE SUSCEPTIBILITY AND INFECTION, AND, PROVIDE DATA MANAGEMENT FOR SITUATIONAL AWARENESS AND ANALYSES. COLUMBIA UNIVERSITY IRVING MEDICAL CENTER WILL SERVE AS A SITE FOR THE RESPIRATORY VIRUS TRANSMISSION NETWORK (RVTN) TO STUDY HOUSEHOLD TRANSMISSION OF INFLUENZA. COLUMBIA UNIVERSITY IRVING MEDICAL CENTER WILL RECRUIT APPROXIMATELY 150 PARTICIPANTS WITH ACUTE INFLUENZA INFECTION AND THEIR HOUSEHOLD MEMBERS TO THE STUDY. USING STUDY MATERIALS PROVIDED BY WASHINGTON UNIVERSITY, COLUMBIA UNIVERSITY IRVING MEDICAL CENTER INVESTIGATORS WILL PROVIDE PARTICIPANTS WITH SELF-COLLECTION MATERIALS, COLLECT QUESTIONNAIRE DATA, MONITOR PARTICIPANT ACTIVITIES, AND RECEIVE COMPLETED SAMPLES. COLUMBIA UNIVERSITY IRVING MEDICAL CENTER WILL STORE SAMPLES IN THE COLUMBIA UNIVERSITY IRVING MEDICAL CENTER LABORATORY AS DIRECTED BY THE PROTOCOL AND SHIP SAMPLES TO WASHINGTON UNIVERSITY OR OTHER DESIGNATED LABORATORY. THE SITE WILL ENTER DATA IN A TIMELY FASHION INTO THE REDCAP DATABASE. THE ONLY SAMPLES TO BE COLLECTED FOR THIS PROJECT ARE NASAL SWABS. SEVEN NASAL SWABS PER PARTICIPANT WILL BE COLLECTED DURING THE STUDY ENROLLMENT PERIOD. THIS IS CONSISTENT ACROSS ALL PARTICIPATING SITES. DATA COLLECTION WILL PRIMARILY FOCUS ON SURVEYS THAT ARE COMPLETED BY STUDY PARTICIPANTS. PARTICIPANTS WILL COMPLETE SEVERAL SURVEYS INCLUDING: A HOUSEHOLD ENROLLMENT SURVEY - THIS WILL BE COMPLETED BY ONE HOUSEHOLD MEMBER AT THE TIME OF STUDY ENROLLMENT AND WILL COLLECT DATA ABOUT THE INDIVIDUALS LIVING IN THE HOUSEHOLD AND THE HOME, ITSELF. A PARTICIPANT ENROLLMENT SURVEY - THIS WILL BE COMPLETED BY EACH PARTICIPANT TO PROVIDE DATA ABOUT DEMOGRAPHICS, HIGH-RISK HEALTH CONDITION”
• UNIVERSITY OF MISSOURI SYSTEM

  UEI GWCTP4CQ1E65 · not in the directory yet

  $15.9K

  Subcontracted by this company · 1 sub-award · latest Jun 3, 2026

  • National Institutes of Health
  • “PURPOSE: THE PROPOSED STUDY WILL PROVIDE CRITICAL INSIGHTS INTO UNDERSTANDING THE MECHANISMS OF HIV NEUROPATHOGENESIS, AGING WITH LONG-TERM HIV AND ART, AND RESEARCH TOWARDS AN HIV CURE.”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.